VELSIPITY (Pfizer Australia Pty Ltd)
Product name
VELSIPITY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
etrasimod arginine
Registration type
NCE/NBE
Indication
VELSIPITY is indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had inadequate response, loss of response or intolerance to conventional, biologic or Janus kinase (JAK) inhibitor therapies.